Physician profile
Marc Bessler
NPI 1033293543
$12,787.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2021: $1,568 · 2022: $3,306 · 2023: $6,301 · 2024: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,040 · Travel and Lodging: $1,592 · Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,040.00 |
| Travel and Lodging | $1,592.33 |
| Food and Beverage | $1,535.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,097.92 | 2022-2023 | Da Vinci Surgical System |
| Ethicon INC. | $3,030.00 | 2022-2023 | Monocryl |
| Medtronic, INC. | $2,365.61 | 2021-2023 | Signia, Ligasure |
| Ethicon US, LLC | $1,515.00 | 2023 | Harmonic, Echelon Flex |
| Boston Scientific Corporation | $907.68 | 2023-2024 | |
| Asensus Surgical, INC. | $600.00 | 2022 | |
| Covidien LP | $590.42 | 2019 | |
| W. L. Gore & Associates, INC. | $270.99 | 2019-2022 | |
| Intra-Sana Laboratories | $202.97 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ambu INC. | $131.76 | 2023 | |
| Novo Nordisk INC | $60.93 | 2023 | Wegovy |
| Genentech USA, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Bessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.